ArticleCureus2026
Study of the Impact of Thyroxine Therapy on Bone Turnover Markers in Primary Hypothyroidism: A Cross-Sectional Comparative Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Hypothyroidism affects skeletal metabolism. Thyroid hormones regulate bone remodeling, and their deficiency may alter bone turnover markers (BTMs), increasing the risk of osteoporosis. Levothyroxine therapy restores euthyroid status, but its impact on bone metabolism requires further evaluation. Aim This study aims to evaluate the effect of levothyroxine therapy in hypothyroidism on thyroid function and bone turnover markers (C-terminal telopeptide of type I collagen (CTX) and procollagen type I N-terminal propeptide (P1NP)). Methods This cross‑sectional comparative study included 150 participants who were further categorized into three groups: Group I (treated hypothyroidism, n=50), Group II (newly diagnosed untreated hypothyroidism, n=50), and Group III (healthy controls, n=50). Baseline clinical data, thyroid function tests (thyroid-stimulating hormone (TSH), total thyroxine (T4), and total triiodothyronine (T3)), and bone turnover markers (serum CTX and P1NP) were measured. For statistical evaluation, chi‑square and one‑way analysis of variance (ANOVA) tests were used, with p<0.05 considered significant. Results Group II showed significantly elevated TSH (12.8±4.6 mIU/mL) with reduced T4 and T3 compared to Groups I and III (p<0.001). Serum CTX was highest in Group II (0.48±0.12 ng/mL) versus Group I (0.32±0.08 ng/mL) and Group III (0.28±0.07 ng/mL) (p<0.01). Similarly, P1NP was elevated in Group II (62±15 ng/mL) compared to Group I (45±12 ng/mL) and Group III (40±10 ng/mL) (p<0.01). Conclusion Untreated hypothyroidism is found to be linked to more bone resorption and compensatory bone formation, while long‑term levothyroxine therapy normalizes thyroid function and stabilizes bone turnover markers. Early treatment and monitoring of BTMs may help prevent skeletal complications in hypothyroid patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.